BMO Capital raised the firm’s price target on LifeStance (LFST) to $10 from $8 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance Health: Strong Q4 Beat, Productivity Gains, and Differentiated Clicks-and-Mortar Model Underscore Undervalued Buy Thesis
- LifeStance Health Guides 2026 Growth, Announces Buyback Program
- LifeStance reports Q4 EPS 2c, consensus 5c
- LifeStance sees FY26 revenue $1.615B-$1.655B, consensus $1.62B.
- LifeStance sees Q1 revenue $380M-$400M, consensus $380.18M